Quintiles Pairs With AstraZeneca
Durham-based Quintiles, the world's largest clinical research organization, has added another major global pharmaceutical company to its expanding list of services.
Just days after announcing a new agreement with Japan's Eisai to shepherd six Eisai cancer drugs to the marketplace, Quintiles unveiled an "industry-leading alliance" with AstraZeneca.
Financial terms were not disclosed, but Quintiles will handle global clinical pharmacology work across multiple therapy areas for AstraZeneca. The deal is aimed at streamlining AstraZeneca's development pipeline.
"This model gives us access to the right scientific and medical expertise plus the quality, flexibility and capacity we need to work efficiently and cost-effectively to deliver these studies," said Anders Ekblom, AstraZeneca executive vice president for global drug development.